NCCN Drugs & Biologics Compendium™

Based directly on the NCCN Clinical Practice Guidelines in Oncology™, the NCCN Drugs & Biologics Compendium™ contains authoritative, scientifically derived information designed to support decision-making about the appropriate use of drugs and biologics in patients with cancer.

Now recognized by UnitedHealthcare for coverage policy, the Compendium is an important source of information. It is referenced by managed care medical directors, pharmacy benefits directors, and other health care professionals who make decisions that impact patient access to appropriate therapy. First released in 2004, the Compendium lists appropriate uses of agents as derived from the NCCN Clinical Practice Guidelines in Oncology™. The uses identified are based upon evaluation of evidence from scientific literature integrated with expert judgment in an evidence-based process. Indicated uses are categorized in a systematic approach that describes the type of evidence available for and the degree of consensus underlying each recommendation. All recommendations are considered to constitute appropriate care. The Compendium lists both FDA-approved uses and appropriate uses beyond the FDA-approved label.